- 全部删除
 
您的购物车当前为空
(1α,1'S,4β)-Lanabecestat is a Beta site APP Cleaving Enzymel (BACE1) inhibitor, and has IC50s of 2.2 nM (TR-FRET assay) and 0.28 nM (sAPPp release assay), respectively.

(1α,1'S,4β)-Lanabecestat is a Beta site APP Cleaving Enzymel (BACE1) inhibitor, and has IC50s of 2.2 nM (TR-FRET assay) and 0.28 nM (sAPPp release assay), respectively.
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 2 mg | ¥ 837  | 5日内发货 | |
| 5 mg | ¥ 1,500  | 5日内发货 | |
| 25 mg | ¥ 5,630  | 8-10周 | |
| 50 mg | ¥ 7,320  | 8-10周 | |
| 100 mg | ¥ 12,400  | 8-10周 | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,620  | 5日内发货 | 
(1α,1'S,4β)-Lanabecestat 相关产品
| 产品描述 | (1α,1'S,4β)-Lanabecestat is a Beta site APP Cleaving Enzymel (BACE1) inhibitor, and has IC50s of 2.2 nM (TR-FRET assay) and 0.28 nM (sAPPp release assay), respectively.  | 
| 别名 | (1α,1'S,4β)-AZD3293 | 
| 分子量 | 412.53 | 
| 分子式 | C26H28N4O | 
| CAS No. | 1384082-96-5 | 
| 密度 | 1.23 g/cm3 (Predicted) | 
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 250 mg/mL (606.02 mM), Sonication is recommended.   | |||||||||||||||||||||||||||||||||||
溶液配制表  | ||||||||||||||||||||||||||||||||||||
DMSO 
  | ||||||||||||||||||||||||||||||||||||
评论内容